missing translation for 'onlineSavingsMsg'
Learn More
Learn More
p14ARF Monoclonal Antibody (14P02 (DCS-240)), Invitrogen™
Mouse Monoclonal Antibody
Brand: Invitrogen MA514260
This item is not returnable.
View return policy
Description
MA5-14260 targets p14ARF/p16beta in ICC/IF, IP, and WB applications and shows reactivity with Human samples. The MA5-14260 immunogen is recombinant p14ARF protein.
The INK4a locus on chromosome 9p21 is frequently affected in human tumors. It encodes two structurally distinct tumor suppressor proteins, p16INK4a and the alternative reading frame protein, ARF (p14ARF in human and P19ARF in mouse). These two proteins interact with the upstream proteins: retinoblastoma protein and p53 tumor suppressors, respectively. Each of these proteins has a role in the senescence of primary cells, activates pathways for cell cycle control and tumor suppression. The p14ARF (or P19ARF in mouse) proteins can induce both G1 and G2 phase arrest in a manner that depends on functional p53. The mouse and human ARF proteins have different functions in tumor suppression; this distinction may contribute to the different levels of tumor proneness of these species.
Specifications
| p14ARF | |
| Monoclonal | |
| 0.2 mg/mL | |
| PBS with 0.2% BSA and 0.09% sodium azide; pH 7.4 | |
| P42771 | |
| CDKN2A | |
| Recombinant p14ARF protein | |
| 500 μL | |
| Primary | |
| Human | |
| Antibody | |
| IgG1 κ |
| Immunocytochemistry, Immunoprecipitation, Western Blot | |
| 14P02 (DCS-240) | |
| Unconjugated | |
| CDKN2A | |
| Alternative reading frame; ARF; ARF-INK4a; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; CDKN2A; cdkn2a {ECO:0000312; cell cycle inhibitor; cell cycle negative regulator beta; cell cycle regulator; CMM2; cyclin dependent kinase inhibitor 2A; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; EMBL:AAL76336.1, ECO:0000312; EMBL:AAL76338.1, ECO:0000312; inhibits CDK4; INK4; INK4A; Ink4a/Arf; INK4a-ARF; mitochondrial smARF; MLM; MTS1; MTS-1; Multiple tumor suppressor 1; P14; p14 p16; P14ARF; p16; p16(INK4a); p16Cdkn2a; P16INK4; p16-INK4; P16INK4A; P16-INK4A; P19; P19 TP16; p19<ARF>; P19ARF; Pctr1; RGD:2323}; TP16; Tumor suppressor ARF | |
| Mouse | |
| Protein G | |
| RUO | |
| 1029 | |
| 4° C | |
| Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
p14ARF Monoclonal Antibody (14P02 (DCS-240)), Invitrogen™ > 500 μL; Unconjugated
Spot an opportunity for improvement?Share a Content Correction
